Allison C. Hoffman Sells 8,426 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $230,114.06. Following the completion of the sale, the general counsel now directly owns 146,126 shares of the company’s stock, valued at approximately $3,990,701.06. This trade represents a 5.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Phreesia Trading Up 0.2 %

Shares of PHR opened at $27.26 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $23.87 and its two-hundred day moving average is $22.97. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The firm has a market capitalization of $1.58 billion, a P/E ratio of -18.55 and a beta of 0.94.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the business posted ($0.58) earnings per share. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. On average, research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on PHR. Truist Financial upped their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Citigroup upped their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. KeyCorp upped their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

Institutional Trading of Phreesia

Several large investors have recently modified their holdings of the business. Trust Point Inc. grew its position in shares of Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after purchasing an additional 607 shares during the last quarter. Ensign Peak Advisors Inc grew its position in shares of Phreesia by 3.2% in the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock valued at $477,000 after purchasing an additional 700 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Phreesia by 3.8% in the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after purchasing an additional 1,120 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $30,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.